Merck KGaA, Darmstadt, Germany

638 articles about Merck KGaA, Darmstadt, Germany

• 

  Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies

  12/6/2023

  In two late-stage trials, the experimental oral drug evobrutinib was unable to significantly reduce annualized relapse rates in MS patients compared with Sanofi’s Aubagio tablets.

• Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

  12/5/2023

  Merck KGaA, Darmstadt, Germany today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (0.11 vs. 0.11 in evolutionRMS 1 and 0.15 for evobrutinib and 0.14 for teriflunomide in evolutionRMS 2, p=NS in both trials)

• MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

  12/5/2023

  MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through Synthia™ retrosynthesis software application programing interface integration.

• Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib

  12/4/2023

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT).

• EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District

  11/14/2023

  EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.

• MilliporeSigma Launches ChemisTwin™, First Ever Digital Reference Material Platform for Analytical Testing

  11/14/2023

  MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, has launched ChemisTwinTM, the first digital reference materials platform that can perform automatic analysis of samples' purity, identification, and degradation of compounds through calibrated algorithm-based digital references.

• Life Science Business of Merck KGaA, Darmstadt, Germany, Wins Sustainability Excellence Award

  11/9/2023

  The Life Science business of Merck KGaA, Darmstadt, Germany was named a World Sustainability Awards 2023 winner at the World Sustainability Awards 2023.

• Huma signs partnership with Merck KGaA, Darmstadt, Germany to support cancer care

  11/7/2023

  Huma Therapeutics, a leading global digital health company, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment.

• Unpacking SMASH Packaging 2.0, MilliporeSigma's Newest Plan To Reduce the Impact of Packaging

  11/1/2023

  The process began in 2019 when the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, launched SMASH Packaging.

• Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

  10/30/2023

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.

• Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies

  10/30/2023

  Jiangsu Hengrui Pharmaceuticals Co., Ltd announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for its next-generation potent and selective PARP1 inhibitor, HRS-1167.

• Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS

  10/11/2023

  Data from the ongoing Phase II open-label extension (OLE) study of evobrutinib show sustained clinical efficacy and a safety profile that remains consistent with that previously reported over five years of therapy - the longest follow-up of any Bruton’s tyrosine kinase inhibitor (BTKi) in multiple sclerosis (MS) studies Additional Phase II OLE data show significant and clinically meaningful improvements on mental health and quality of life measures in study participants with relapsing

• EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

  10/10/2023

  EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of new analyses from the MAVENCLAD® tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis experienced sustained reduction in serum neurofilament light chain, indicating that MAVENCLAD reduced neuronal injury over two years.

• Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration

  9/28/2023

  Quris-AI, an artificial intelligence innovator disrupting the pharmaceutical arena, announced the extension of its collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

• Sparking Curiosity Across the U.S. With MilliporeSigma’s Curiosity Cube

  9/20/2023

  The Curiosity Cube, a 22x10-foot shipping container turned mobile science lab from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has been hard at work sparking kids' interest in STEM careers on its fifth annual U.S tour.

• Merck KGaA, Darmstadt, Germany, Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

  9/20/2023

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence -driven design and discovery capabilities, further advancing the company’s research efforts.

• Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

  9/20/2023

  Exscientia plc announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology.

• MilliporeSigma Leaders Receive Business Intelligence Group Sustainability Awards

  9/18/2023

  In recognition of their contributions to sustainable business practices, two leaders from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, were selected as recipients in the Business Intelligence Group 2023 Sustainability Awards program.

• Breaking New Ground: Merck KGaA, Darmstadt, Germany’s Major Life Science Solar Energy Initiative Powers Up at Darmstadt Site

  7/24/2023

  By 2030, Merck KGaA, Darmstadt, Germany's sustainability strategy aims for a 50% reduction in Scope 1 and Scope 2 emissions as compared to 2020.

• First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib

  7/18/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814).